Matrix metalloproteinases in autism spectrum disorders by unknown
JMP
Abdallah and Michel Journal of Molecular Psychiatry 2013, 1:16
http://www.jmolecularpsychiatry.com/content/1/1/16REVIEW Open AccessMatrix metalloproteinases in autism spectrum
disorders
Morsi W Abdallah1,2* and Tanja M Michel1Abstract
Autism Spectrum Disorders (ASD) are group of developmental disabilities with a complex neurobiological basis
including putative changes in the immune system. They are characterized by pervasive qualitative abnormalities
in social interactions, communication, and stereotyped behaviour. Matrix metalloproteinases (MMPs) represent a
group of proteases which play an important role in neuroinflammation and neurodevelopment. Therefore, they
possibly have a crucial function in the etiopathology of ASD. In this review, we summarize the plausibility of the
hypothesis that MMPs are involved in the neuropathology of ASD. Possible pathways through which MMPs can
contribute to the pathogenesis of ASD are discussed including neuroinflammatory mechanisms inclusive of
mediating neuropathological effects of infections, the associations between MMPs and other biomarkers such as
cytokines, chemokines and neurotrophic factors. Despite sufficient evidence for such an involvement of MMPs in
the neuropathology of ASD, they have not yet been extensively studied in this context. Thus, further research in
this field is not only urgently needed but also very promising and may also lead to new therapeutic approaches.
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Introduction
Matrix metalloproteinases (MMPs), discovered back in
1962, are a family of at least 28 endopeptidases. They
encompass a large family of proteases and share many
similarities in their structure, regulation and function [1].
In their active form, MMPs play a number of important
roles not only in physiological conditions but also in
pathological states [2]. They are essential for various
physiological processes such as embryonic development,
morphogenesis and remodelling. Furthermore, they have
been implicated in a number of key pathologic processes
including inflammation, fibrosis, arthritis and cancer [1].
Additionally, MMPs play a crucial role in the develop-
ment of the central nervous system (CNS) and neuro-
genesis as well as during phases of neuroinflammation
[2,3], a frequently reported finding in children with
Autism Spectrum Disorders (ASD) [4].
Autism spectrum disorders (ASD), or pervasive develop-
mental disorders (PDD), as termed in the International* Correspondence: morsi.abdallah@med.uni-rostock.de
1Department of Psychiatry and Psychotherapy, Rostock University Medical
Center, Gehlsheimer Straße 20, Rostock 18147, Germany
2Department of Child and Adolescent Neuropsychiatry, Rostock University
Medical Center, Gehlsheimer Str. 20, Rostock 18147, Germany
© 2013 Abdallah and Michel; licensee BioMed
Creative Commons Attribution License (http:/
distribution, and reproduction in any mediumClassification of Diseases, 10th version [5], refer to a group
of heterogeneous neurodevelopmental disorders charac-
terized by qualitative impairments in social interaction,
communication and repetitive stereotypic behaviour [6,7].
While accumulating evidence suggests that immune
processes play a key role in the pathophysiology of
ASD [8], no definitive biologic screening or diagnostic
tools have been universally accepted, and the diagnostic
standards are still based on behavioural criteria [6].
This review first introduces briefly members of the
MMPs and their biochemistry. This is followed by a
short description of their physiological functions within
CNS as well as their involvement in pathological states.
The review focuses mainly on the potential pathways
through which MMP’s can contribute to the etiopathology
of ASD.The structure and biochemistry of MMPs
MMPs along with the ADAMs (A Disintegrin And
Metalloproteinase) and the ADAMTs (A Disintegrin
And Metalloproteinase with Thrombospondin Motifs)
are subgroups of the larger metzincin superfamily [9] that
are collectively able to process and degrade various
extracellular matrix (ECM) proteins. Based on theirCentral Ltd. This is an Open Access article distributed under the terms of the
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which include collagenases (such as MMP-1), stromelysins
(MMP-3), gelatinases (MMP-2, MMP-7 and MMP-9), and
membrane type metalloproteinases (MT-MMPs) such as
(MMP-14) [2].
While MMPs were initially described to be the products
macrophages and neutrophils acting on collagen, they
are now known to be produced by different tissues and
cell types, including osteoblasts, human umbilical vein
endothelial cells, smooth muscle cells and keratinocytes
[10]. They often bind with heparin sulphate glycosami-
noglycans on the cell surface and have wide range of
substrates [11].
The regulation of MMPs is complex starting at gene
transcription, posttranslational activation of zymogens, and
endogenous inhibition [12]. The synthesis and secretion
of MMPs take place in inactive forms which are later
activated by the loss of a 10-kDa propeptide either
intracellularly or extracellularly. The activity of MMPs
is balanced by the endogenous tissue inhibitors of me-
talloproteinases (TIMPs) and by α2-macroglobulin. The
resulting equilibrium between production, activation,
and inhibition prevents excessive proteolysis or inhib-
ition [2,10].
MMPs in the CNS
MMPs play an important role in the development of the
CNS as well as during pathological periods of inflam-
mation and injury. Substrates of MMPs have important
functions in normal CNS development during synap-
togenesis, synaptic plasticity, and long-term potentiation
(LTP) [13]. Several animal studies have documented the
presence of different MMPs such as MMP-9 and MMP-2
in the brain [2,13]. MMPs are mainly secreted by astro-
cytes and microglia within the CNS due to different
triggers [14].
Alteration of MMPs expression has been detected in
the nervous system in response to injury or neurological
disease [15,16]. MMPs have the ability to mediate the
disruption of the blood brain barrier (BBB) by degrading
the tight junctions’ proteins and basal lamina proteins,
thereby leading to BBB leakage, leukocyte infiltration,
brain edema, and hemorrhage. Furthermore, they regulate
ECM protein destruction, remodelling and tissue inflam-
mation in response to oxidative stress [17]. Additionally,
several reports have illustrated MMPs involvement in wide
range of neurological pathologies such meningitis [18],
multiple sclerosis [19], Alzheimer’s disease [15], inflam-
matory myopathies [20] and tumors of the CNS such as
glioma [21].
Possible role of MMPs in the etiopathology of ASD
The neurobiological basis of ASD is complex, and several
lines of research suggest that both genetic and envir-onmental factors contribute etiologically to ASD [22,23].
Despite the extensive ongoing research, convergence
towards a universal molecular pathway is still lacking,
and ASD is still considered to have an idiopathic etiology
in many individuals [22]. Although MMPs have been
extensively investigated in several somatic and psychi-
atric disorders [10,24], their role in the etiopathology of
ASD have been less extensively examined. Most of the
research in this field has been targeting MMPs levels in
individuals with Fragile-X Syndrome (FXS) [25], a disorder
where at least 30% of patients have features of ASD [26].
Several animal models of FXS have reported elevated
levels of MMPs in the CNS [27]. This drove the main
interest in this area was targeted toward Minocycline,
an antibiotic which is widely used to treat acne and other
skin infections but also inhibits matrix metalloproteinase
(MMP)-9 [28]. Although the application of this drug to
FXS patient in several clinical trials have revealed positive
improvements in language, attention and behavioural
improvements, research in this area is still ongoing [29].
Interestingly, in a recent study by Abdallah et al., [16],
amniotic fluid samples for 331 ASD cases and 698 fre-
quency-matched controls were analyzed for levels of
MMP-9 along with other biomarkers utilizing a Danish
historic birth cohort and Danish nationwide health reg-
isters Our results showed elevated levels of MMP-9 in
ASD cases compared with controls and this was unre-
lated to FXS.
Contribution of MMPs to the etiopathology of ASD
is biologically plausible through direct and indirect path-
ways which are not necessarily mutually exclusive. Several
studies have reported disrupted synaptic pathways in
some cases of ASD [30] along with abnormal formation
of neuronal connections or elimination of inappropriate
connections [31]. Besides, anomalies of brain structure
have repeatedly been reported in cases with ASD [32].
MMPs play important roles in neuronal development
and neuroplasticity [33]. They have also important func-
tions in reactive synaptogenesis following brain injury
[27]. Interestingly, several neuronal activity altered genes
associated with ASD such as those encoding Neurexin
(NRXN1) and Neuroligin (NLGN3) are processed by
MMPs. Furthermore, elevated levels of MMPs can
induce hyperplasticity state within the CNS that even-
tually leads to ASD, fitting well within the hyper-
reactivity/hyperplasticity model of the disease [34]. It
is not clear though whether MMPs act directly or as
an epiphenomenon to lead ultimately to ASD. This
sheds the light on the potential role of MMPs in
modulating neuroplasticity and neurogenesis indir-
ectly through interaction with molecules such as neu-
roligins, integrins and growth factors [13].
MMPs can activate several neurotrophic factors (NFs),
such as Brain-derived neurotrophic factor (BDNF), through
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regulate neuronal survival, development, and synaptic
plasticity [35].
Theoretically speaking, MMPs can also contribute to
ASD pathology, on one hand, through inducing a neuro-
inflammatory state or through disruption of the BBB
leaving the normally protected milieu of the CNS more
vulnerable to the systemic circulation [36]. On the other
hand, MMPs have also the ability to act through different
inflammatory markers associated with ASD pathology
through their proteolytic activity. Such markers include
cytokines, chemokines, and reactive oxygen species (ROS)
[37,38].
MMPs have the ability to regulate various inflammatory
processes at different levels including epithelial repair,
defence mechanisms against microorganisms and through
modulatory effects on cytokines and chemokines [39].
Furthermore, elevated levels of MMPs were reported in
Experimental Allergic Encephalomyelitis (EAE), an animal
model of a monophasic inflammatory demyelinating ill-
ness associated with ASD and other neuropsychiatric
diseases. Interestingly, applying MMPs inhibitors has
also showed antinflammatory effects [40]. Given that
neuroimmune factors can directly affect brain develop-
ment and that neuroinflammation can be a critical patho-
genic factor in the development of ASD [4], MMPs can
serve as important candidates to better understand the
underlying neurodevelopmental pathology in ASD.
The triad of infections, ASD and MMPs is of special
importance. Several studies have reported associations
between infections and ASD. Such associations were
proposed as early as 1963, with Dr. Krevelen reporting
congenital rubella infection in a patient with infantile
autism [41]. Both Congenital infections [42-44] and
postnatal childhood infections [45,46] were associated
with high rate of ASD. On the other arm of the triad is
the association between infections and MMPs. Elevated
levels of MMPs (specifically MMP-1) were found associ-
ated with bacterial meningitis [18] and were correlated
with cerebral injury and infection severity during infection.
Also, there is an increased ROS-induced activity of MMPs
during viral infections as a result of intracellular signalling
by virion components or cytotoxic effects of viral non-
structural proteins [47]. Probably, the direct contribution
of infections to the rising ASD prevalence is limited
[48]. However, their role triggering an inflammatory
state is rather important [49]. Taken together, it is possible
that MMPs can intermediate the neuropathological effects
of infections (and probably other environmental insults)
which eventually contribute to the development of ASD.
There is also growing evidence regarding the important
role of cytokines and chemokines in mediating inflam-
matory effects on the neurodevelopmental trajectory in
autism and other psychiatric disorders such as schizo-phrenia [50]. MMPs can regulate inflammatory response
through their modulatory effects on cytokines and chemo-
kines [39]. Accumulating evidence shows that MMPs
can either promote or repress inflammation through
proteolytic processing of inflammatory cytokines and
chemokines [1]. For example, MMPs have the ability to
amplify inflammatory response through activating cyto-
kines such as Tumor necrosis factors α (TNF-α), Interleu-
kin 1β (IL-1β) and wide range of chemokines. Elevated
levels of TNF- α in amniotic fluid [51] cerebrospinal fluid
[52], peripheral blood mononuclear cells [53,54], whole
blood samples [55] and post mortem brain tissue of
autistic individuals [56] were repeatedly reported. Simi-
lar finding were also reported for IL-1 [57,58].
MMPs have also the ability through their cleavage
mechanisms and proteolytic processing to regulate che-
mokines gradient, and therefore, control the influx of leu-
kocytes [59]. Chemokines have been repeatedly reported
to be associated with ASD [60]. For example, we reported
recently elevated levels of monocyte chemotactic protein-
1 (MCP-1) (a CC chemokine encoded on human chromo-
some 17) in amniotic fluid samples of cases that developed
ASD later in life [61]. Interestingly chemokines share
overlapping pathways with MMPs through which they
contribute to the neuropathology of ASD. The role of
some chemokines (such as MCP-1) in neuroinflammation
has been well established using the animal model of EAE
where a positive correlation between the expression and
the degree of inflammation in the CNS was reported [62].
Furthermore, this chemokine can act similarly to MMPs
and induce BBB breakdown [63].
Taken together, MMPs can contribute to the etiopa-
thology of ASD through several pathways which are
not necessarily mutually exclusive. MMPs can modu-
late neuroplasticity and neurogenesis and contribute to
a hyperplasticity state associated with ASD. Their patho-
logic proteolytic effects on the BBB can also leave the
CNS vulnerable to the systemic circulation in critical
developmental periods. Furthermore, MMPs can hinder
neurodevelopment through inducing neuroinflammatory
state within the CNS and through their proteolytic effects
on NFs, cytokines and chemokines.
Conclusion
MMPs encompass a large family of proteases that share
many similarities in their structure, regulation and func-
tion. These enzymes play crucial role not only in the
normal development of the central nervous system but
also in a number of key pathologic processes including
inflammation, fibrosis, arthritis and cancer. Contribution
of MMPs to the etiopathology of ASD is biologically
plausible through direct and indirect pathways that are
not necessarily mutually exclusive. This includes their role
in neuroinflammation, BBB disruption and their modula-
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kines, chemokines and NFs. While MMPs have been
extensively studied in several pathologies, their role in
ASD was less extensively examined. In this review we
presented the current evidence of MMPs contribution to
ASD pathology. Despite the biologic plausibility, further
research in this area including examining levels of MMPs
in different stages during pregnancy and after birth is
needed to identify their pattern in ASD and their asso-
ciations with other markers such as cytokines and NFs.
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